These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 16908838)

  • 1. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
    Fulci G; Breymann L; Gianni D; Kurozomi K; Rhee SS; Yu J; Kaur B; Louis DN; Weissleder R; Caligiuri MA; Chiocca EA
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12873-8. PubMed ID: 16908838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis.
    Wakimoto H; Fulci G; Tyminski E; Chiocca EA
    Gene Ther; 2004 Jan; 11(2):214-23. PubMed ID: 14712306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
    Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
    J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.
    Fulci G; Dmitrieva N; Gianni D; Fontana EJ; Pan X; Lu Y; Kaufman CS; Kaur B; Lawler SE; Lee RJ; Marsh CB; Brat DJ; van Rooijen N; Stemmer-Rachamimov AO; Hochberg FH; Weissleder R; Martuza RL; Chiocca EA
    Cancer Res; 2007 Oct; 67(19):9398-406. PubMed ID: 17909049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.
    Kurozumi K; Hardcastle J; Thakur R; Yang M; Christoforidis G; Fulci G; Hochberg FH; Weissleder R; Carson W; Chiocca EA; Kaur B
    J Natl Cancer Inst; 2007 Dec; 99(23):1768-81. PubMed ID: 18042934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.
    Zemp FJ; McKenzie BA; Lun X; Reilly KM; McFadden G; Yong VW; Forsyth PA
    Cancer Res; 2014 Dec; 74(24):7260-73. PubMed ID: 25336188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity.
    Friedman A; Tian JP; Fulci G; Chiocca EA; Wang J
    Cancer Res; 2006 Feb; 66(4):2314-9. PubMed ID: 16489036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.
    Lun X; Alain T; Zemp FJ; Zhou H; Rahman MM; Hamilton MG; McFadden G; Bell J; Senger DL; Forsyth PA
    Cancer Res; 2010 Jan; 70(2):598-608. PubMed ID: 20068158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
    Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
    J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses.
    Ikeda K; Ichikawa T; Wakimoto H; Silver JS; Deisboeck TS; Finkelstein D; Harsh GR; Louis DN; Bartus RT; Hochberg FH; Chiocca EA
    Nat Med; 1999 Aug; 5(8):881-7. PubMed ID: 10426310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
    Okemoto K; Wagner B; Meisen H; Haseley A; Kaur B; Chiocca EA
    PLoS One; 2013; 8(8):e71932. PubMed ID: 23936533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
    Kambara H; Saeki Y; Chiocca EA
    Cancer Res; 2005 Dec; 65(24):11255-8. PubMed ID: 16357128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varicella zoster virus infection of malignant glioma cell cultures: a new candidate for oncolytic virotherapy?
    Leske H; Haase R; Restle F; Schichor C; Albrecht V; Vizoso Pinto MG; Tonn JC; Baiker A; Thon N
    Anticancer Res; 2012 Apr; 32(4):1137-44. PubMed ID: 22493342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
    Hellums EK; Markert JM; Parker JN; He B; Perbal B; Roizman B; Whitley RJ; Langford CP; Bharara S; Gillespie GY
    Neuro Oncol; 2005 Jul; 7(3):213-24. PubMed ID: 16053696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
    Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
    Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.
    Sandmair AM; Turunen M; Tyynelä K; Loimas S; Vainio P; Vanninen R; Vapalahti M; Bjerkvig R; Jänne J; Ylä-Herttuala S
    Cancer Gene Ther; 2000 Mar; 7(3):413-21. PubMed ID: 10766347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.